A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly

The study aims to demonstrate that pasireotide-induced hyperglycemia can be effectively and safely managed in majority of patients, including those with diabetes at start of pasireotide treatment.
Phase 4
NCT02060383
Neuroscience - Growth Hormone Deficiency, Neuroscience
Kevin Yuen, MD
Lauren Lennox

Inclusion Criteria:
  • Patients greater than or equal to 18 years old
  • Confirmed diagnosis of Cushing's disease or acromegaly
Exclusion Criteria:
  • Patients who require surgical intervention
  • Patients receiving DPP-4 inhibitors or GLP-1 receptor agonists within 4 weeks prior to study entry
  • HbA1c > 10 % at screening
  • Known hypersensitivity to somatostatin analogues Other protocol-defined inclusion/exclusion criteria may apply.
Lauren Lennox
206-320-4355
206-320-2604